Cercar
01/01/2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).
01/01/2023
The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:3.000(Q2/3D).
01/01/2023
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis
Ryan C., Puig L., Zema C., Thompson E.H.Z., Yang M., Wu E., Bensimon A., Huang X., Joshi A.D., Elewski B.. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:12.800(Q1/1D).
16/12/2022
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients
Chicharro, P, Llamas-Velasco, M, Armesto, S, Acosta, EH, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, De-la-Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Rodriguez, OB, Feltes, R, Riera-Monroig, J, Dauden, E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12)DOI:10.1111/dth.15929. PMID:36223184. IF:3.600(Q1/3D).
02/12/2022
Biologic treatment of psoriasis in oncologic patients
Rusinol, L, Camina-Conforto, G, Puig, L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12)DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4.600(Q2/3D).
01/11/2022
Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study
Lopez-Ferrer, A, Vilarrasa, E, Armesto, S, Santos-Juanes, J, Galache, C, Carretero, G, Sahuquillo, A, Salgado-Boquete, L, del Alcazar, E, Gonzalez-Cantero, A, Martorell, A, Rivera-Diaz, R, Mitxelena-Ezeiza, J, Mateu, A, Belinchon, I, Llamas-Velasco, M, Riera-Monroig, J, Lazaro, A, Lopez-Estebaranz, JL, Gich, I, Puig, L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11)DOI:10.1111/dth.15831. PMID:36109488. IF:3.600(Q1/3D).
01/09/2022
Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting
Reolid, A, Armesto, S, Sahuquillo-Torralba, A, Torres, T, Feltes, R, Vilarrasa, E, Belincho, I, de la Cueva, P, Rodriguez, L, Romero-Mate, A, Vidal, D, Coto-Segura, P, Herrera-Acosta, E, Riera-Monroig, J, Salgado, L, Llamas-Velasco, M, Dauden, E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3)DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13.800(Q1/1D).
01/09/2022
SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain)
Piron, M, Jane, M, Ciruela, P, Basile, L, Martinez, A, Puig, L, Bes, M, Sauleda, S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5)DOI:10.2450/2022.0232-21. PMID:35175189. IF:3.700(Q2/4D).